Antibody fragments, especially Fabs, are getting increased attention as potential biopharmaceuticals because they have some advantages over monoclonal antibodies (Mabs). For example, Fabs show improved pharmacokinetics for tissue penetration and can bind to targets inaccessible to conventional antigen-binding sites.

The product is a part of Cytiva's Custom Designed resins program.